Get Premium to unlock powerful stock data

NAS:HALO (USA) Healthcare » Biotechnology

Halozyme Therapeutics Inc $ 33.24 0.89 (2.75%)

Volume:

1,166,013

Avg Vol (1m):

807,887

Market Cap $:

4.68 Bil

Enterprise Value $:

4.61 Bil

PE Ratio:

11.91

PB Ratio:

16.66

Also Trade In: Germany Mexico UK

EMBED

5D 3M YTD 1Y 3Y 5Y 10Y All 10Y -%

Above Low: +NaN%

Below High: NaN%

Peers

Financial Strength

5/10

	Current	Vs Industry
Cash-To-Debt	0.93
Equity-to-Asset	0.24
Debt-to-Equity	3.11
Debt-to-EBITDA	3.12
Interest Coverage	28.27
Piotroski F-Score	4	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	4.95	DISTRESS GREY SAFE
Beneish M-Score	0.77	Not Manipulator Manipulator
WACC vs ROIC		ROIC 167.89% WACC 8.66%

Profitability Rank

3/10

	Current	Vs Industry	Vs History
Operating Margin %	64.14
Net Margin %	88.36
ROE %	284.47
ROA %	47.77
ROC (Joel Greenblatt) %	155.08
3-Year Revenue Growth Rate	-6
3-Year EBITDA Growth Rate	20.6
3-Year EPS without NRI Growth Rate	26.5

Warning Signs » HALO's Warning Signs

Valuation Rank

	Current	Vs Industry	Vs History
PE Ratio	11.91
Forward PE Ratio	19.06
PE Ratio without NRI	11.91
Price-to-Owner-Earnings	13.67
PB Ratio	16.66
PS Ratio	10.58
Price-to-Free-Cash-Flow	18.45
Price-to-Operating-Cash-Flow	18.26
EV-to-EBIT	17.34
EV-to-EBITDA	17.15
EV-to-Revenue	10.4
EV-to-FCF	17.68
Current Ratio	8.99
Quick Ratio	8.5
Cash Ratio	7.21
Days Inventory	247
Days Sales Outstanding	81.03
Days Payable	9.14

Dividend & Buy Back

	Current	Vs Industry	Vs History
3-Year Average Share Buyback Ratio	1.8

Valuation & Return

	Current	Vs Industry	Vs History
Price-to-Tangible-Book	16.62
Price-to-Intrinsic-Value-Projected-FCF	8.13
Price-to-Median-PS-Value	0.66
Price-to-Graham-Number	2.97
Earnings Yield (Greenblatt) %	5.77

Product

Business

Information

About

Affiliate Program

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names

Earn affiliate commissions by embedding GuruFocus Charts

GuruFocus Affiliate Program: Earn up to $400 per referral. Detailed

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investers. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at anytime. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.